Active Clinical Trials — Longevity Supplements
Live registry of ongoing human clinical trials for the supplements covered in our protocol pages — pulled from ClinicalTrials.gov.
Last updated: March 2026
💊 Rapamycin
Results Published 2025
185 healthy adults aged 50–85. Rapamycin 5 or 10 mg weekly vs placebo for 1 year. First major RCT of rapamycin in non-transplant humans for longevity. Mixed results on safety/healthspan metrics after 1 year.
💊 Metformin
Active · Enrolling
3,000 non-diabetic participants aged 65–79. First FDA-approved trial treating “aging” as a condition. Metformin 1,500 mg/day vs placebo. Primary endpoint: composite of age-related conditions (cancer, cardiovascular, dementia, mortality). Estimated completion 2027.
💊 NMN / NAD+ Precursors
Published 2022
108 healthy men aged 40–60. NMN 250 mg/day for 12 weeks. Significant increase in blood NAD+ levels; modest improvements in muscle strength and walking speed. No serious adverse events. Published in GeroScience.
Published 2018
120 healthy adults. Nicotinamide Riboside (NR) 300 mg and 1,000 mg/day vs placebo. Dose-dependent increase in whole blood NAD+. First human RCT confirming NR raises NAD+. Published in Nature Communications.
💊 Omega-3 / Fish Oil
Published 2025
2,157 European adults aged 70+. Omega-3 1g/day + vitamin D 2,000 IU + exercise vs placebo combinations for 3 years. Individually and combined, interventions slowed biological aging on epigenetic clocks. Published in Nature Aging, 2025.
💊 Senolytics (Quercetin + Dasatinib)
Active · Phase 2
Intermittent dosing of D+Q senolytic combination in Alzheimer’s patients. Reducing senescent cell burden as potential neuroprotective strategy. Estimated completion 2026.
💊 Spermidine
Published 2021
100 older adults with subjective cognitive decline. Spermidine-rich plant extract 3 months. Improved mnemonic discrimination capacity vs placebo. Published in Alzheimer’s & Dementia: Translational Research.
